Daré Bio CEO flags Ovaprene interim Phase 3 results as potential catalyst in investor interview
DARE•CEO outlines commercialization plans and pipeline milestones
- Daré Bioscience management outlined its shift from development-stage to commercial-stage in a Virtual Investor CEO Connect interview.
- CEO Sabrina Martucci Johnson highlighted the launch of Flora Sync LF5, with DARE to PLAY Sildenafil Cream positioned as the next revenue driver.
- Plans center on building a scalable commercial infrastructure to support multiple products, with emphasis on customer acquisition, provider engagement, and market access.
- Ovaprene posted positive interim Phase 3 results, with DARE-HPV advancing into Phase 2.
- Johnson flagged potential value catalysts over the next 12-18 months tied to commercialization progress and clinical milestones.
